Clinical trials: Iris Tumor
Kaposi Sarcoma, Human Immunodeficiency Virus
Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
Kaposi sarcoma (KS) has an unpredictable course, patients with disseminated KS starting combined Antiretroviral Therapy can develop Immune Reconstitution Syndrome (IRIS), with a severe clinical presentation and high mortality…
- Conditions
- Kaposi Sarcoma, Human Immunodeficiency Virus, Immune Reconstitution Syndrome
- Trial name
- NCT03296553
- Testing
- Valganciclovir, Antiretroviral Combinations
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- National Institute of Cancerología
Barrett's Esophagus Without Dysplasia, Barrett's Esophagus With Dysplasia
Volumetric Laser Endomicroscopy With Intelligent Real-time Image Segmentation (IRIS)
This is a prospective randomized clinical trial examining how IRIS (Intelligent Real-time Image Segmentation) affects biopsy patterns in VLE (Volumetric laser endomicroscopy).
- Conditions
- Barrett's Esophagus Without Dysplasia, Barrett's Esophagus With Dysplasia, Barrett's Esophagus With Low Grade Dysplasia, Barrett's Esophagus With High Grade Dysplasia
- Trial name
- NCT03814824
- Testing
- IRIS (Intelligent real-time image segmentation), VLE (Volumetric laser endomicroscopy)
- Where
- 3 sites in United States
- Volunteers
- 148 people
- Sponsor
- Northwell Health
Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes…
- Conditions
- Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma
- Trial name
- NCT00243061
- Testing
- cediranib maleate
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma
- Trial name
- NCT01100528
- Testing
- recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Case Comprehensive Cancer Center
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
This phase II trial is studying how well sorafenib works when given together with carboplatin and paclitaxel in treating patients with stage IV melanoma of the eye.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma
- Trial name
- NCT00329641
- Testing
- carboplatin, paclitaxel, sorafenib tosylate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
This phase I/II trial studies the side effects and best dose of liposomal irinotecan and rucaparib when given together with fluorouracil and leucovorin calcium and to see how well they work in treating patients with pancreatic…
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm
- Trial name
- NCT03337087
- Testing
- Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Academic and Community Cancer Research United
Pancreatic Cancer
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
This is an open-label, phase 2 non-comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients not previously treated for metastatic…
- Trial name
- NCT02551991
- Testing
- nal-IRI, 5 fluorouracil, Leucovorin
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 56 people
- Sponsor
- Ipsen
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00482911
- Testing
- cyclophosphamide, lenalidomide, sunitinib malate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma
- Trial name
- NCT00450255
- Testing
- ziv-aflibercept, pharmacological study
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
This clinical trial studies giving radiation therapy to the liver in patients with uveal (eye) melanoma who have a specific chromosome loss (monosomy 3) or are DecisionDx Class 2 and therefore more likely to have their disease…
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Stage IIA Uveal Melanoma, Stage IIB Uveal Melanoma
- Trial name
- NCT02336763
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by…
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Uveal Melanoma
- Trial name
- NCT00121225
- Testing
- vorinostat
- Where
- 5 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Metastatic Intraocular Melanoma
- Trial name
- NCT01413191
- Testing
- Cixutumumab, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Intraocular Melanoma
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00738361
- Testing
- nab-paclitaxel
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has…
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension
- Trial name
- NCT01989572
- Testing
- Laboratory Biomarker Analysis, Sargramostim, Tyrosinase Peptide
- Where
- 148 sites in United States
- Volunteers
- 815 people
- Sponsor
- National Cancer Institute (NCI)
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body.
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma
- Trial name
- NCT01143402
- Testing
- Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 33 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00084656
- Testing
- ipilimumab, Tyrosinase/gp100/MART-1 Peptides
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bristol-Myers Squibb